d) response to intervention
The response to intervention by modulator therapy was assessed by evaluating the change in LCI between baseline, i.e. before treatment start and after at least two weeks of treatment in three different treatment groups: In (i) either Orkambi® (Lumacaftor/Ivacaftor) or Symdeko® (Tezacaftor/Ivacaftor)-treated patients (double modulator therapy), in (ii) Trikafta® (Elexacaftor/Tezacaftor/Ivacaftor)–treated patients (triple modulator therapy), and (iii) patients who received first Orkambi® or Symdeko® followed by Trikafta® (combined modulator therapy). Response to intervention was defined as within-group changes from baseline to under treatment and analyzed by paired t-tests.
Results

3.1 Study population

Summaries for demographical characteristics and number of measurements included are presented in Table 1.